Deluca, C., Beyer, M., Drew, H., Murray, J., Massey, J., Koffman, B., Battiato, K., Gribben, J. G., Lamanna, N., & Russomanno, C. (2023). The Value of Collaboration with Patient Advocacy Organizations to Enhance Initiatives Focused on Patient-Centered Care and Improve Outcomes in Chronic Lymphocytic Leukemia. Blood, 142(Supplement 1), 3715–3715. https://doi.org/10.1182/blood-2023-177959

Lipsky, A. H., Hill, B. T., Winter, A., Bachow, S. H., Viny, A. D., Rosenblat, T. L., Jurcic, J., & Lamanna, N. (2023). Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions. Blood, 142(Supplement 1), 3274–3274. https://doi.org/10.1182/blood-2023-189718

DiPersio, J., Cooper, B. W., Suh, H. C., Koura, D., Bernard, L., Shah, N. N., Walter, R. B., Perales, M.-A., Mapara, M., Tamari, R., Loken, M. R., Breitschwerdt, K., Nath, S., Raffel, G. D., & Koehne, G. (2023). Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT). Blood, 142(Supplement 1), 483–483. https://doi.org/10.1182/blood-2023-190037

Xu-Monette, Z. Y., Li, Y., Snyder, T., Yu, T., LU, T., Tzankov, A., Visco, C., Bhagat, G., Qian, W., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F., Go, H., Ponzoni, M., Ferreri, A. J. M., Møller, M., … Young, K. H. (2023). Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma. Blood, 142(Supplement 1), 429–429. https://doi.org/10.1182/blood-2023-179972

Biran, N., Dhakal, B., Niesvizky, R., Lentzsch, S., McKay, J. T., Vesole, D. H., Nooka, A. K., Paul, B., Hari, P. N., Stork-Sloots, L., D’Ambrosi, S., Kuiper, R., van Vliet, M., Siegel, D. S., Usmani, S. Z., & van Rhee, F. (2023). Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival. Blood, 142(Supplement 1), 2013–2013. https://doi.org/10.1182/blood-2023-181905

Jajosky, R. P., Patel, K. R., Allen, J. W. L., Zerra, P. E., Chonat, S., Ayona, D., Maier, C. L., Morais, D., Wu, S.-C., Luckey, C. J., Eisenbarth, S. C., Roback, J. D., Fasano, R. M., Josephson, C. D., Manis, J. P., Chai, L., Hendrickson, J. E., Hudson, K. E., Arthur, C. M., & Stowell, S. R. (2023). Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression. Blood, 142(12), 1082–1098. https://doi.org/10.1182/blood.2022018591

Zhou, N., Choi, J., Grothusen, G., Kim, B.-J., Ren, D., Cao, Z., Liu, Y., Li, Q., Inamdar, A., Beer, T., Tang, H.-Y., Perkey, E., Maillard, I., Bonasio, R., Shi, J., Ruella, M., Wan, L., & Busino, L. (2023). DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance. Blood, 142(11), 973–988. https://doi.org/10.1182/blood.2022018752

Akpan, I. J., & Hunt, B. J. (2023). How I approach the prevention and treatment of thrombotic complications in hospitalized patients. Blood, 142(9), 769–776. https://doi.org/10.1182/blood.2021014835

Carson, J. L., & Brittenham, G. M. (2023). How I treat anemia with red blood cell transfusion and iron. Blood, 142(9), 777–785. https://doi.org/10.1182/blood.2022018521

Feng, J., Hsu, P.-F., Esteva, E., Labella, R., Wang, Y., Khodadadi-Jamayran, A., Pucella, J., Liu, C. Z., Arbini, A. A., Tsirigos, A., Kousteni, S., & Reizis, B. (2023). Haplodeficiency of the 9p21 tumor suppressor locus causes myeloid disorders driven by the bone marrow microenvironment. Blood, 142(5), 460–476. https://doi.org/10.1182/blood.2022018512

Ku, A., & Alobeid, B. (2023). IRF4/DUSP22-positive anaplastic large cell lymphoma arising in the setting of chronic olecranon bursitis. Blood, 141(23), 2912–2912. https://doi.org/10.1182/blood.2023019992

Jajosky, R. P., Patel, S. R., Wu, S.-C., Patel, K. R., Covington, M. L., Vallecillo-Zúniga, M. L., Ayona, D., Bennett, A., Luckey, C. J., Hudson, K. E., Hendrickson, J. E., Eisenbarth, S. C., Josephson, C. D., Zerra, P. E., Stowell, S. R., & Arthur, C. M. (2023). Prior Immunization to an Intracellular Antigen Enhances Subsequent Red Blood Cell Alloimmunization in Mice. Blood. https://doi.org/10.1182/blood.2022016588

Etra, A., Capellini, A., Alousi, A., Al Malki, M. M., Choe, H., DeFilipp, Z., Hogan, W. J., Kitko, C. L., Ayuk, F., Baez, J., Gandhi, I., Kasikis, S., Gleich, S., Hexner, E., Hoepting, M., Kapoor, U., Kowalyk, S., Kwon, D., Langston, A., … Levine, J. E. (2023). Effective treatment of low-risk acute GVHD with itacitinib monotherapy. Blood, 141(5), 481–489. https://doi.org/10.1182/blood.2022017442

Hod, E. A., Brittenham, G. M., Bitan, Z. C., Feit, Y., Gaelen, J. I., La Carpia, F., Sandoval, L. A., Zhou, A. T., Soffing, M., Mintz, A., Schwartz, J., Eng, C., Scotto, M., Caccappolo, E., Habeck, C., Stern, Y., McMahon, D. J., Kessler, D. A., Shaz, B. H., … Spitalnik, S. L. (2022). A randomized trial of blood donor iron repletion on red cell quality for transfusion and donor cognition and well-being. Blood, 140(25), 2730–2739. https://doi.org/10.1182/blood.2022017288

Chakraborty, R., Rybicki, L., Wei, W., Valent, J., Faiman, B. M., Samaras, C. J., Anwer, F., & Khorana, A. A. (2022). Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score. Blood, 140(23), 2443–2450. https://doi.org/10.1182/blood.2022015727

Brown, J. R., Eichhorst, B., Hillmen, P., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Kaźmierczak, M., Jurczak, W., Zhou, K., Šimkovič, M., Mayer, J., Gillespie-Twardy, A. L., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., … Shadman, M. (2022). Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study. Blood, 140(Supplement 2), LBA-6-LBA-6. https://doi.org/10.1182/blood-2022-171538

de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A., Dogan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., Morin, R. D., Nadel, B., Pileri, S. A., Rosenquist, R., Rossi, D., Salaverria, I., Steidl, C., Treon, S. P., Zelenetz, A. D., … Scott, D. W. (2022). Genomic profiling for clinical decision making in lymphoid neoplasms. Blood, 140(21), 2193–2227. https://doi.org/10.1182/blood.2022015854

Zeidan, A. M., Platzbecker, U., Garcia-Manero, G., Sekeres, M. A., Fenaux, P., DeZern, A. E., Greenberg, P. L., Savona, M. R., Jurcic, J. G., Verma, A. K., Mufti, G. J., Buckstein, R., Santini, V., Shetty, J. K., Ito, R., Zhang, J., Zhang, G., Ha, X., Backstrom, J. T., & Komrokji, R. S. (2022). Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood, 140(20), 2170–2174. https://doi.org/10.1182/blood.2022016171

Di Meo, F., Iyer, A., Akama, K., Yu, C., Cheng, R., Cesarano, A., Marino, S., Aljoufi, A., Soni, R., Roda, J. M., Sissons, J., Vu, L. P., Guzman, M. L., Huang, K., Roodman, D. G., & Perna, F. (2022). A Novel Bi-Specific T-Cell Engager Targeting ILT3 Is Potently Effective in Multiple Myeloma. Blood, 140(Supplement 1), 671–672. https://doi.org/10.1182/blood-2022-167584

Jajosky, R. P., Allen, J. W., Zerra, P. E., Maier, C. L., Chonat, S., Luckey, C. J., Roback, J. D., Fasano, R. M., Josephson, C. D., Manis, J. P., Chai, L., Hendrickson, J. E., Hudson, K. E., Arthur, C. M., & Stowell, S. R. (2022). Antibody-Mediated Antigen Loss Can Switch an Augmented Immune Response to Antibody-Mediated Immunosuppression. Blood, 140(Supplement 1), 73–74. https://doi.org/10.1182/blood-2022-170081

Stiefel, J., Flower, A. M., Botwinick, M., Ford, M., Foti, A., Gandhi, M., Slovin, J., Smilow, E., Bowers, A., Karpel, H., Schwartz, L. Y., Fraint, E., Gennarini, L. M., Gardner, S. L., Raetz, E. A., Shah, N. C., Chen, J., Krajewski, J., Hijiya, N., … Sulis, M. L. (2022). Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL. Blood, 140(Supplement 1), 7763–7765. https://doi.org/10.1182/blood-2022-160272

Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Dasgupta, K., & Ramscar, N. (2022). ASC4KIDS: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood, 140(Supplement 1), 12204–12205. https://doi.org/10.1182/blood-2022-162451

Smaldone, A., Manwani, D., Aygun, B., Appiah-Kubi, A., Smith-Whitley, K., & Green, N. S. (2022). Assessing Multi-Level Barriers to Medication Adherence in Youth with Sickle Cell Disease Using Pharmacy-Based Prescription Refill Data. Blood, 140(Supplement 1), 2149–2150. https://doi.org/10.1182/blood-2022-157527

Seymour, J. F., Byrd, J. C., Munir, T., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O’Brien, S., Brown, J. R., Mato, A. R., Stilgenbauer, S., Fehn, T., de Miranda, P. A. P., Higgins, K., John, E., de Borja, M., Jurczak, W., & Woyach, J. A. (2022). Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood, 140(Supplement 1), 7050–7052. https://doi.org/10.1182/blood-2022-157060

McCurdy, A., Seow, H., Pond, G. R., Gayowsky, A., Chakraborty, R., Visram, A., Kaedbey, R., D’Souza, A., Mohyuddin, G. R., Fonseca, R., & Mian, H. S. (2022). Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada. Blood, 140(Supplement 1), 427–429. https://doi.org/10.1182/blood-2022-157815

Roy, I., Epperla, N., Shouse, G., Romancik, J. T., Moyo, T. K., Kenkre, V. P., Ollila, T. A., Fitzgerald, L. A., Hess, B. T., Evens, A. M., Zurko, J., Chowdhury, S. M., Annunzio, K., Ferdman, R., Bhansali, R. S., Harris, E. I., Sorrell, M., Liu, J., Nizamuddin, I. A., … Karmali, R. (2022). Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy. Blood, 140(Supplement 1), 2416–2418. https://doi.org/10.1182/blood-2022-163822

Davids, M. S., Sharman, J. P., Eyre, T. A., Woyach, J. A., de Miranda, P. A. P., Shahkarami, M., Butturini, A., Emeribe, U., & Byrd, J. C. (2022). Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features. Blood, 140(Supplement 1), 4173–4175. https://doi.org/10.1182/blood-2022-157018

Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter-Brown, L. C., Izutsu, K., Daugherty, M., Brammer, J. E., Mehta-Shah, N., Pro, B., & Horwitz, S. M. (2022). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis. Blood, 140(Supplement 1), 9387–9389. https://doi.org/10.1182/blood-2022-169432

Capellini, A., Etra, A., Alousi, A. M., Al Malki, M. M., Choe, H., Defilipp, Z., Hogan, W. J., Kitko, C. L., Ayuk, F. A., Baez, J., Gandhi, I., Kasikis, S., Gleich, S., Hexner, E. O., Hoepting, M., Kapoor, U., Kowalyk, S., Kwon, D., Langston, A., … Levine, J. E. (2022). Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy. Blood, 140(Supplement 1), 1867–1869. https://doi.org/10.1182/blood-2022-156000

Frangoul, H., Locatelli, F., Bhatia, M., Mapara, M. Y., Molinari, L., Sharma, A., Lobitz, S., de Montalembert, M., Rondelli, D., Steinberg, M., Walters, M. C., Imren, S., Zhang, L., Sharma, A., Song, Y., Simard, C., Hobbs, W., & Grupp, S. (2022). Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease. Blood, 140(Supplement 1), 29–31. https://doi.org/10.1182/blood-2022-162353

Locatelli, F., Lang, P., Li, A., Corbacioglu, S., de la Fuente, J., Wall, D. A., Liem, R., Meisel, R., Mapara, M. Y., Shah, A. J., Cappellini, M. D. D., Kattamis, A., Sheth, S., Bobruff, Y., Bower, L., Zhang, L., Sharma, A., Song, Y., Hobbs, W., & Frangoul, H. (2022). Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. Blood, 140(Supplement 1), 4899–4901. https://doi.org/10.1182/blood-2022-166881

Mato, A. R., Woyach, J. A., Brown, J. R., Ghia, P., Patel, K., Eyre, T. A., Munir, T., Lech-Marańda, E., Lamanna, N., Tam, C. S., Seymour, J. F., Shah, N. N., Coombs, C. C., Ujjani, C. S., Patel, M. R., Fakhri, B., Cheah, C. Y., Alencar, A. J., Cohen, J. B., … Jurczak, W. (2022). Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 2316–2320. https://doi.org/10.1182/blood-2022-159497

Wang, M. L., Shah, N. N., Jurczak, W., Zinzani, P. L., Eyre, T. A., Cheah, C. Y., Ujjani, C. S., Koh, Y., Izutsu, K., Gerson, J. N., Flinn, I. W., Tessoulin, B., Alencar, A. J., Ma, S., Lech-Marańda, E., Rhodes, J. M., Patel, K., Woyach, J. A., Lamanna, N., … Mato, A. R. (2022). Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 9368–9372. https://doi.org/10.1182/blood-2022-159425

Wierda, W. G., Lewis, D. J., Ghia, P., Shah, N. N., Coombs, C. C., Cheah, C. Y., Lamanna, N., Rhodes, J. M., Hoffmann, M., Ma, S., Eyre, T. A., Munir, T., Patel, M. R., Alencar, A. J., Tam, C. S., Seymour, J. F., Jurczak, W., Lech-Marańda, E., Roeker, L. E., … Mato, A. R. (2022). Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 846–849. https://doi.org/10.1182/blood-2022-157058

Fahmy, L., Yang, H. R., Kwinta, B., Beylergil, V., Schreidah, C. M., Schwartz, L. H., & Geskin, L. J. (2022). Evaluation of Volumetric Lymph Node Measurements in Cutaneous T-Cell Lymphoma Patients Enrolled in the Mavoric Trial: An Interim Analysis. Blood, 140(Supplement 1), 3700–3700. https://doi.org/10.1182/blood-2022-163711

Zhang, C., Tremblay, D., Magnotti, J., Ronner, L., Podoltsev, N. A., Gotlib, J., Heaney, M. L., Kuykendall, A., O’Connell, C. L., Fleischman, A. G., Mesa, R., Yacoub, A., Mascarenhas, J., & Shammo, J. M. (2022). Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis. Blood, 140(Supplement 1), 9693–9695. https://doi.org/10.1182/blood-2022-157873

Chapman-Fredricks, J. R., Thakkar, D., Alderuccio, J. P., Naresh, K. N., Ondrejka, S. L., Hsi, E. D., Xu, M. L., Paulson, N., Koff, J. L., Jaye, D. L., Cohen, J. B., Ortved Gang, A., Leeman-Neill, R. J., Dave, T., Happ, L., Love, C., Zandi, S., Naushad, H., Mason, E. F., … Lossos, I. S. (2022). Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site. Blood, 140(Supplement 1), 6378–6380. https://doi.org/10.1182/blood-2022-165616

Chakraborty, R., Behera, T. R., Li, H., Dean, R. M., Hill, B. T., Jagadeesh, D., Winter, A., Anwer, F., Pohlman, B., Sobecks, R. M., Hamilton, B. K., & Majhail, N. S. (2022). Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study. Blood, 140(Supplement 1), 10926–10927. https://doi.org/10.1182/blood-2022-166904

Byrd, J. C., Woyach, J. A., Furman, R. R., Martin, P., O’Brien, S., Brown, J. R., Stephens, D. M., Barrientos, J. C., Patten, P. E., Munir, T., Patel, K., Butturini, A., de Borja, M., Wang, M. H., Jain, N., & Wierda, W. G. (2022). Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up. Blood, 140(Supplement 1), 9865–9867. https://doi.org/10.1182/blood-2022-159542

Estrella, B., Pazos, M. A., Ricker, E. C., Ryu, Y. K., Piorczynski, T. B., Liu, Y., Tolu, S., & Amengual, J. E. (2022). First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade. Blood, 140(Supplement 1), 358–359. https://doi.org/10.1182/blood-2022-166929

George, S. A., Veludhandi, A., Xiang, Y., Stenger, E., Arnold, S. D., Mehta, A., Schirmer, D. A., Spencer, J. B., Guilcher, G. M., Bhatia, M., Abraham, A., Gomez-Lobo, V., Krishnamurti, L., & Meacham, L. R. (2022). Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study. Blood, 140(Supplement 1), 1391–1392. https://doi.org/10.1182/blood-2022-168060

Granat, L. M., Li, H., Anwer, F., Sheu, M., Faiman, B. M., Khouri, J., Mazzoni, S., Valent, J., Samaras, C. J., Chakraborty, R., Chaulagain, C. P., van Heeckeren, W. J., & Williams, L. S. (2022). Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma. Blood, 140(Supplement 1), 4290–4291. https://doi.org/10.1182/blood-2022-168040

Platzbecker, U., Komrokji, R. S., Fenaux, P., Zeidan, A. M., Sekeres, M. A., Savona, M. R., Madanat, Y. F., Santini, V., Van Eygen, K., Raza, A., Germing, U., Berry, T., Dougherty, S., Shah, S., Sun, L., Huang, F., Feller, F., Wan, Y., Ikin, A., & Sherman, L. (2022). Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study. Blood, 140(Supplement 1), 1106–1108. https://doi.org/10.1182/blood-2022-169050

Melody, M., St. Pierre, F., Helenowski, I., Pearse, W. B., Vakkalagadda, C. V., Leventhal, J. R., Friedewald, J., Ho, B., Ganger, D., Winter, J. N., Gordon, L. I., Lin, A. Y., Karmali, R., Ma, S., Pro, B., & Moreira, J. (2022). Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 6674–6675. https://doi.org/10.1182/blood-2022-164724

Blachly, J. S., Stephens, D. M., Ye, J. C., Lamanna, N., Jain, N., Niesman, M., Zhang, K., & Woyach, J. A. (2022). Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL. Blood, 140(Supplement 1), 2324–2325. https://doi.org/10.1182/blood-2022-171203

Qiu, A., Wang, L., Dei Zotti, F., Hudson, K. E., Hod, E. A., & La Carpia, F. (2022). Iron Overload and Iron-Induced Microbiome Changes May Affect Lymphoid Levels Post Bone Marrow Transplant and Graft-Versus-Host Disease Survival in Mice. Blood, 140(Supplement 1), 2465–2466. https://doi.org/10.1182/blood-2022-167300

Usmani, S., Patel, K., Hari, P., Berdeja, J., Alsina, M., Vij, R., Raje, N., Leleu, X., Dhodapkar, M., Reshef, R., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Ananthakrishnan, R., Greggio, C., Favre-Kontula, L., Sternas, L., & San-Miguel, J. (2022). KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation. Blood, 140(Supplement 1), 875–877. https://doi.org/10.1182/blood-2022-162469

Walters, M. C., Thompson, A. A., Kwiatkowski, J. L., Parikh, S., Mapara, M. Y., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Miller, A., Zhang, L., Chawla, A., Macari, E. R., Pierciey, F. J., Tisdale, J. F., & Kanter, J. (2022). Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study. Blood, 140(Supplement 1), 26–28. https://doi.org/10.1182/blood-2022-162288

Li, S., Fu, J., Yang, J., Ma, H., Mapara, M. Y., Marcireau, C., & Lentzsch, S. (2022). MAP4K2 Inhibition Reinforces the Iberdomide Sensitivity in MM Cells By Inducing IKZF1 Degradation through a CRBN Independent Mechanism. Blood, 140(Supplement 1), 4224–4225. https://doi.org/10.1182/blood-2022-168314

Koff, J. L., Kositsky, R., Jaye, D. L., Churnetski, M. C., Baird, K., O’Leary, C. B., Flowers, C. R., Leppa, S., Karjalainen-Lindsberg, M.-L., Li, S., Xu, J., Pedersen, M. Ø., Gang, A. O., Naresh, K. N., Leeman-Neill, R. J., Au Yeung, K. H. R., Qureishi, H. N., Iqbal, J., Chapman-Fredricks, J. R., … Cohen, J. B. (2022). Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma. Blood, 140(Supplement 1), 3500–3503. https://doi.org/10.1182/blood-2022-168002